1. |
Ranieri V, Rubenfeld GD, Thompson B, et al. Acute respiratory distress syndrome:the Berlin Definition. JAMA, 2012, 307:2526-2533.
|
2. |
Villar J, Sulemanji D, Kacmarek RM, et al. The acute respiratory distress syndrome:incidence and mortality, has it changed? Curr Opin Crit Care, 2014, 20:3-9.
|
3. |
Pirat A, Zeyneloglu P, Aldemir D, et al. Pretreatment with simvastatin reduces lung injury related to intestinal ischemia-reperfusion in rats. Anesth Analg, 2006, 102:225-232.
|
4. |
Jacobson JR, Barnard JW, Grigoryev DN, et al. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol, 2005, 288:L1026-1032.
|
5. |
Yao HW, Mao LG, Zhu JP. Protective effects of pravastatin in murine lipopolysaccharide-induced acute lung injury. Clin Exp Pharmacol Physiol, 2006, 33:793-797.
|
6. |
Craig TR, Duffy MJ, Shyamsundar M, et al. A randomized clinical trial of hydroxymethylglutaryl-coenzyme a reductase inhibition for acute lung injury (The HARP Study). Am J Respir Crit Care Med, 2011, 183:620-626.
|
7. |
Truwit JD, Bernard GR, Steingrub J, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med, 2014, 370:2191-2200.
|
8. |
McAuley DF, Laffey JG, O'Kane CM, et al. Simvastatin in the acute respiratory distress syndrome. N Engl J Med, 2014, 371:1695-1703.
|
9. |
Shyamsundar M, McAuley DF, Shields MO, et al. Effect of simvastatin on physiological and biological outcomes in patients undergoing esophagectomy:a randomized placebo-controlled trial. Ann Surg, 2014, 259:26-31.
|
10. |
Mansur A, Steinau M, Popov AF, et al. Impact of statin therapy on mortality in patients with sepsis-associated acute respiratory distress syndrome (ARDS) depends on ARDS severity. BMC Med, 2015, 13:128.
|
11. |
Furlan AD, Pennick V, Bombardier C, et al. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine, 2009, 34:1929-1941.
|
12. |
Bein T, Grasso S, Moerer O, et al. The standard of care of patients with ARDS:ventilatory settings and rescue therapies for refractory hypoxemia. Intensive Care Med, 2016, 42:699-711.
|
13. |
董亮, 邱海波.急性肺损伤的治疗进展.中华急诊医学杂志, 2012, 21:235-238.
|
14. |
Cepkova M, Matthay MA. Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. J Intensive Care Med, 2006, 21:119-143.
|
15. |
Calfee CS, Matthay MA. Nonventilatory treatments for acute lung injury and ARDS. Chest, 2007, 131:913-920.
|
16. |
Yadav H, Lingineni RK, Slivinski EJ, et al. Preoperative statin administration does not protect against early postoperative acute respiratory distress syndrome:a retrospective cohort study. Anesth Analg, 2014, 119:891-898.
|
17. |
Kor DJ, Iscimen R, Yilmaz M, et al. Statin administration did not influence the progression of lung injury or associated organ failures in a cohort of patients with acute lung injury. Intensive Care Med, 2009, 35:1039-1046.
|
18. |
Dinglas VD, Hopkins RO, Wozniak AW, et al. One-year outcomes of rosuvastatin versus placebo in sepsis-associated acute respiratory distress syndrome:prospective follow-up of SAILS randomised trial. Thorax, 2016, 71:401-410.
|
19. |
Grimaldi D, Durand A, Gleeson J, et al. Failure of statins in ARDS:the quest for the "Holy Grail" continues. Minerva Anestesiol, 2016.[Epub ahead of print].
|
20. |
Fernandes V, Santos MJ, Pérez A. Statin-related myotoxicity. Endocrinol Nutr, 2016, 63:239-249.
|